CSIMarket Company Name, Ticker, Industry, else..
 
Provectus Biopharmaceuticals Inc   (PVCT)
Other Ticker:  
 
 
Price: $0.0749 $0.00 0.000%
Day's High: $0.0749 Week Perf: -11.36 %
Day's Low: $ 0.07 30 Day Perf: -10.94 %
Volume (M): 216 52 Wk High: $ 0.15
Volume (M$): $ 16 52 Wk Avg: $0.10
Open: $0.07 52 Wk Low: $0.04



 Market Capitalization (Millions $) 35
 Shares Outstanding (Millions) 473
 Employees 23
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals Inc is a biotechnology company that focuses on developing innovative therapies for cancer and dermatological conditions. The company specializes in developing small molecule drugs and biologics that target specific molecular pathways involved in the progression of these diseases.

Provectus Biopharmaceuticals is best known for its drug candidate PV-10, which is being developed for the treatment of skin cancer, including metastatic melanoma. PV-10 is a selective small molecule drug that is injected directly into tumors, causing them to shrink or disappear. The drug has demonstrated promising results in clinical trials, showing high rates of complete response and minimal side effects.

In addition to its work on PV-10, Provectus Biopharmaceuticals is also involved in developing other drug candidates for various cancer types and dermatological conditions. The company utilizes its expertise in oncology, immunology, and molecular biology to develop novel therapies that have the potential to address unmet medical needs.

Overall, Provectus Biopharmaceuticals Inc is a biotechnology company that is dedicated to developing innovative therapies for cancer and dermatological conditions, with a particular focus on personalized medicine and targeted therapies.


   Company Address: 800 S Gay St Knoxville 37929 TN
   Company Phone Number: 594-5999   Stock Exchange / Ticker: PVCT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -5.81%    
EBS   -0.48%    
HCM   -12.19%    
REGN   -3.69%    
TEVA   -0.24%    
VTRS   -0.56%    
• View Complete Report
   



Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Inc Shines with Impressive Revenue Growth in First Quarter of 2024



In the fast-paced world of the stock market, investors are constantly on the lookout for companies that show promising growth potential. Despite facing challenges in the financial period ending March 31, 2024, Provectus Biopharmaceuticals Inc has managed to maintain its revenue elevation, providing a new revelation to many investors.
Revenue Growth Amidst Declining Industry Trend:
While the Major Pharmaceutical Preparations industry has experienced a slight decline in top-line, Provectus Biopharmaceuticals Inc has defied the odds and displayed an impressive revenue rise of 16.119% to $0.24 million. This is remarkable, considering the negative trend witnessed in the industry, which saw a decline of -0.32%. This achievement highlights Provectus Biopharmaceuticals Inc's ability to adapt and thrive in a challenging market environment.
Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Inc Strives for Innovation in Cancer Therapies as Revenue Takes a Dip in Recent Fiscal Period

Provectus Biopharmaceuticals Inc. is a biotechnology company that focuses on developing innovative cancer therapies. The company's primary goal is to harness the power of the body's own immune system to target and destroy cancer cells. Provectus has been at the forefront of cutting-edge research in the field of oncology, and their efforts have led to numerous breakthroughs in the treatment of various types of cancer.
In the fourth quarter of 2023, Provectus Biopharmaceuticals Inc. achieved balanced books, with earnings per share of $0.00. This marks a significant improvement from the previous year, when earnings per share were also $0.00. The company's revenue for the quarter decreased by -26.527% to $0.12 million from $0.16 million in the same period the year before. However, there was a significant sequential revenue increase of 73.677% from $0.07 million.
Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Inc Faces Severe Revenue Plunge and Net Shortfall in Q3 2023



Provectus Biopharmaceuticals Inc, a notable player in the healthcare industry, recently released its financial results for the fiscal period closing on September 30, 2023. However, the numbers painted a disappointing picture for the company, as it experienced a substantial decrease in revenue and a larger net shortfall compared to the previous year. Let's dive deeper into the details of these results and their potential implications for the stock market.
Revenue Plunge and Earnings:
During the fiscal period closing on September 30, 2023, Provectus Biopharmaceuticals Inc witnessed a severe decline in revenue. It plummeted by a staggering 77.855% compared to the same quarter a year ago, reaching a mere $0.07 million compared to $0.31 million. Moreover, when comparing the previous quarter, the revenue experienced a sharp sequential tumble of 56.913% from $0.16 million.
Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Inc Faces Sharp Drop in Revenue, Reporting Zero Gain in the April to June 2023 Fiscal Interval

Financial News Report:
Provectus Biopharmaceuticals Inc Reports Zero Gain during April to June 2023 Fiscal Interval
During the fiscal interval of April to June 30, 2023, Provectus Biopharmaceuticals Inc reported zero gain of $0.00 per share, similar to the previous year. This figure also represents a decline from the preceding financial reporting period, where the gain was $0.00 per share.
Furthermore, the company experienced a significant decrease in revenue during the comparable financial reporting period a year ago. The revenue decreased by 49.693% to $0.16 million from $0.32 million. Sequentially, the revenue fell by 21.062% from $0.21 million.
Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Inc Sets Earnings Record with $0.205025 Million in Q1 Revenue

Provectus Biopharmaceuticals reports $0.205025 million in revenue for Q1 of 2023
Provectus Biopharmaceuticals Inc, a leading pharmaceutical preparations company, has reported a revenue of $0.205025 million in the first quarter of 2023 earnings season. This is a significant increase over the similar quarter a year ago when the company reported a deficit of $-1.239 million.
The company has had a positive start to the financial year, with a net shortfall of $-0.827 million instead of a deficit in the first quarter. This impressive improvement is due to Provectus Biopharmaceuticals? commitment to innovation and technological advancements in the field of pharmaceuticals.






Provectus Biopharmaceuticals Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com